A first time in man, study to assess the safety of AZD8329 after single ascending oral doses
Study identifier:D2350C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, single-blind, placebo-controlled, two-centre phase I study in healthy volunteers to assess the safety, tolerability and pharmacokinetics of AZD8329 after single ascending oral doses
Medical condition
Healthy men
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD8329, Placebo
Sex
Male
Actual Enrollment
119
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Jul 2009
Primary Completion Date: 01 Aug 2010
Study Completion Date: 01 Aug 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD8329 AZD8329 oral solution | Drug: AZD8329 Oral solution, single ascending doses |
| Placebo Comparator: Placebo Placebo for AZD8329 oral solution | Drug: Placebo Oral solution, placebo |
Contacts
Investigators
Principal Investigator
Wolfgang Kühn
Quintiles AB, Phase I Services, Uppsala, Sweden
